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Thehuman zona pellucida glycoprotein-3 (hZP3) by virtueof its critical role during fertilization has been proposedas a promising
candidate antigen to develop acontraceptive vaccine. Inthisdirection, it isimperative to map minimal motifsofthe Bcell epitopes
(BCEs) so as to avoid ZP-speciﬁc oophoritogenic T cell epitopes (TCEs) in the ZP3-based immunogens. In this study, based on
known results of mapping marmoset and bonnet monkey ZP3 (mstZP3 and bmZP3), two predictable epitopes
23–30 and 301–320 on
hZP3 were ﬁrst conﬁrmed and ﬁve minimal motifs within four epitopes on hZP3 were deﬁned using serum to recombinant
hZP3a
22–176 or hZP3b
177–348 as well as a biosynthetic peptide strategy. These deﬁned minimal motifs were QPLWLL
23–28 for
hZP3
23–30,M Q V T D D
103–108 for hZP3
93–110, EENW
178–181 for hZP3
172–190, as well as SNSWF
306–310 and EGP
313–315 for hZP3
301–320,
respectively. Furthermore, the antigenicity of two peptides for hZP3
172–187 and hZP3
301–315 and speciﬁcity of the antibody response
to these peptides were also evaluated, which produced high-titer antibodies in immunized animals that were capable of reacting
to ZP on human oocytes, r-hZP3b
177–348 protein, as well as r-hZP3
172–190,r - h Z P 3
303–310, and r-hZP3
313–320 epitope peptides fused
with truncated GST188 protein.
1.Introduction
The human zona pellucida (hZP) is an extracellular matrix
surrounding eggs, which consists of four sulfated glycopro-
teins designated as ZP1, ZP2, ZP3, and ZP4 [1, 2]. ZP glyco-
proteins mediate several critical events during fertilization
process such as initial recognition and binding of the sper-
matozoa to the egg in a species-speciﬁc manner, induction of
theacrosomereactioninthezona-boundspermatozoon,and
prevention of polyspermy [3, 4]. By virtue of their critical
role during fertilization, ZP glycoproteins have been pro-
posed as target for developing contraceptive vaccines [5, 6].
Although active immunization with puriﬁed or recombinant
ZP (r-ZP) proteins induces infertility in various mammalian
species, the contraceptive eﬃcacy is invariably associated
with either transient alteration or complete loss of ovarian
function [7–10]. The observed ovarian pathology following
active immunization with ZP antigens may be due to (i)
presence of ZP-speciﬁc T-cell epitopes (TCE) within a B-cell
epitope (BCE), for example peptide corresponding to mouse
ZP3(mZP3)aminoacid(aa)residues330–342(peptide
330–342)
[11], (ii) autoimmune ovarian disease (AOD) that can be
adoptively transferred by the ZP3 peptide-activated CD4+
T-cells to na¨ ıve recipients but does not occur when only
antipeptide antibodies are administered [12], and (iii) the
minimal and modiﬁed BCE peptide
335–342 of mZP3, which
had no longer a ZP-speciﬁc TCE (phenylalanine, a key resi-
dueofthe“oophoritogenic”TCE,substitutedbyalanine),in-
ducedinfertilityinmicewitheightdiﬀerenthaplotypeswith-
out any AOD when it was co-linearly synthesized with a
foreign “promiscuous” TCE [13].
Theaboveobservationsclearlysuggestanewpossibleap-
proach of developing BCE peptide-based ZP vaccines for fer-
tilitycontrol,whichshouldbedevoidofanyZP-speciﬁcTCE.2 Clinical and Developmental Immunology
Therefore, eﬀorts have been made by several laboratories to
delineate infertility-associated BCEs of ZP proteins since a
BCE on mZP3 was ﬁrst identiﬁed by Dean et al. [14]. For in-
stance, ﬁve BCE peptides
45–64, 93–110, 137–150, 172–190 and 334–341
of hZP3 have been mapped [15–17] and additional two
epitopes corresponding to aa residue 23–30 and 301–320 of
hZP3 have also been predicted based on the mapping results
of marmoset ZP3 (mstZP3) and bonnet monkey (Macaca
radiata;bmZP3)proteins[18,19],becausetheiraasequences
are highly conserved among mstZP3 and hZP3 as well as
bmZP3 and hZP3 proteins. To eliminate potential oophori-
tis-inducing TCE within a mapped longer BCE peptide, the
identiﬁcation of minimal motif of mapped BCEs on hZP3
has been hampered due to the limitation of available map-
ping methods. So far, only the minimal motif of the BCE on
the C-terminus of hZP3 has been identiﬁed using rabbit
serum [16].
We have reported previously the identiﬁcation of a min-
imal motif of hZP4
314–319 epitope using improved peptide
biosynthesis strategy for the ﬁrst time, where the trun-
cated streptavidin (Stv108) and glutathione S-transferase
(GST188) were used as protein carrier, respectively [20].
In addition, the sera against r-hZP3
22–176 (hZP3a) and
r-hZP3
177–348 (hZP3b) were made, which reacted with hu-
man oocyte [21]. Therefore, the main aim of the present
study was to map minimal motifs of four linear BCEs
on hZP3 with biosynthetic peptides and antibodies against
r-hZP3a or r-hZP3b. Moreover, the immunogenicity of two
chemically synthesized peptides
171–186 and 301–315 of hZP3,
conjugated to keyhole limpet hemocyanin (KLH), has also
been evaluated in rabbits.
2.MaterialsandMethods
2.1. Plasmids, Antibodies, and Peptides. The plasmids
pXXStv-3 and pXXGST-1 were used to express various bio-
synthetic peptides in E. coli [20]. Rabbit sera against r-hZP3a
and r-hZP3b prepared as described previously were used for
BCE identiﬁcation and minimal motif mapping [21]. Pep-
tides FSLRLMEENWNAEKRS (P1) and SFSKPSNSWF-
PVEGP (P2) corresponding to hZP3
172–187 and hZP3
301–315
as well as PETQPGPLTLELQIAKDK (P3) corresponding to
hZP4
308–325 were produced on an APEX396 synthesizer by
Sangon Co. (Shanghai, China), with more than 90% purity
on HPLC. The peptides P1 and P2 were used as antigens to
test antibody against P1 or P2 by ELISA, and peptide P3 was
used as unrelated control peptide in ELISA.
2.2. Other Reagents. All chemicals were purchased from
Sangon Co. unless otherwise stated.
2.3. Biosynthesis of 6/8mer–20mer Peptides. As e to fb i o s y n -
thetic peptides (numbering P4–P11) corresponding to P4
(QPLWLLQG), P5 (ECQEATLMVMVSKDLPGTGK), P6
(EVGLHECGNSMQVTDDAL),P7(PIECRYPRQGNVSS),P8
(FSLRLMEENW), P9 (FSLRLMEENWNAEKRSPTF), P10
(SFSKPSNSWFPVEGPADICD), and P11 (RRQPHVMS) of
hZP3
23–30, 45–64, 93–110, 137–150, 172–181, 172–190, 301–320 and 334–341
were expressed in E. coli as truncated GST188 or Stv108
fusion proteins as described earlier [20]. Similarly, four sets
of35overlapping6–8merpeptides(P12–P46)corresponding
to P4, P6, P9, and P10 sequences were also made, which
overlapped each other by 5–7 residues.
Brieﬂy, the synthesized annealed DNA fragments encod-
ing each P4 to P46 peptides corresponding to the hZP3
cDNA sequence [22], incorporating BamH I and TAA-Sal I
cohesive end on their 5  and 3  ends, were inserted into the
BamH I and Sal I sites downstream of the Stv108 or GST188
gene in pXXStv-3 or pXXGST-1 plasmid. The resultant re-
combinant plasmids expressing each target short peptide
fused with Stv108 or GST188 protein were transformed into
the BL21(DE3)(pLysS) E. coli strain (Novagen, Inc., Madi-
son, Wis, USA). Each recombinant clone was ﬁrst grown in
3mL of Luria Broth (LB) containing 100μgm L −1 ampicillin
at 30◦C with continuous shaking at 200rpm overnight. Next
day, 60μL of cell suspension was inoculated in 3mL of
fresh LB and grown until the cell density reached 0.6–0.8 at
OD600, and then further grown for 4h at 42◦C to induce
expressionoftherecombinantprotein.Forscreeningpositive
recombinant clones, each cell pellet harvested from induced
target clones was ﬁrst used to run SDS-PAGE gel using the
pellet containing Stv108 or GST188 protein expressed by
pXXStv-4 or pXXGST-2 plasmid as negative controls, and
nucleotide (nt) sequence of all the recombinant clones were
subsequentlydetermined(UnitedGeneHoldingLtd.,Shang-
hai). The cell pellets containing each short peptide fusion
protein were stored at −20◦C.
2.4. SDS-PAGE and Western Blotting. Cell pellets obtained
from 3mL culture were boiled in 400μL of 1x sample load-
ing buﬀer for 5min and proteins were resolved by SDS-
PAGE under reducing conditions using 15% gels [23]. Gels
were either stained with Coomassie brilliant blue G-250 for
analyzing the bands of fusion proteins or processed for
Western blot by electrotransferring the proteins onto 0.2μm
nitrocellulose membrane (Whatman GmbH, Dossel, Ger-
many) [24]. Complete transfer of proteins was ensured by
staining the nitrocellulose membrane with 0.1% (w/v) Pon-
ceauS.Nitrocellulosemembranewassubsequentlyprocessed
for Western blotting using rabbit antisera against r-hZP3a
and r-hZP3b (1:300 dilution in PBS containing 0.05%
Tween20and1%skimmilkpowder)orimmuneseraagainst
P1 or P2 (1:2000 dilution). Speciﬁc antigen-antibody react-
ions on the membrane were visualized by using goat anti-
rabbit IgG conjugated to horseradish peroxidase (HRP)
(Proteintech Group, Inc., Chicago, Ill, USA) at 1:1000 dilu-
tion.Theblotwasdevelopedbyusing3,3 -diaminobenzidine
(DAB) (Sigma, Mo, USA) in 50mM PBS containing 0.05%
H2O2. The reaction was stopped by washing the membrane
extensively with MQ water. In some cases, enhanced chemi-
luminescence was also performed using ECL plus Western
blotting detection reagents (GE Healthcare, Buckingham-
shire, UK) according to the manufacturer’s instructions.
2.5. Immunization of Animals. Care and treatment of the an-
imals was based on the standard laboratory animal careClinical and Developmental Immunology 3
protocols approved by the Institutional Animal Care Com-
mittee. Six male New Zealand White rabbits were obtained
fromSIPPR-BKLabAnimalCo.,Ltd.(Shanghai,China).The
immunization schedule was as follows: six rabbits (number
073–076) weighing 2.0 ± 0.5kg were immunized intramus-
cularly with 0.5mg of chemically synthesized peptide P1 or
P2conjugatedwithKLH(Sigma)andemulsiﬁedincomplete
Freund’sadjuvant(CFA)(Sigma)atmultiplesitesontherab-
bit’s back, respectively. The animals were boosted three times
intramuscularly with 0.25mg of same peptide antigen emul-
siﬁed in incomplete Freund’s adjuvant (Sigma) at 2 week
intervals. Serum samples from immunized animals were col-
lected 7 days after the third booster, and the antibody titer
was assessed by ELISA. Nonimmune sera from two animals
(number 077-078) who only received CFA and P3 as unre-
lated peptide antigen were used as negative controls in the
ELISA, respectively.
2.6. ELISA and Immunoﬂuorescence
2.6.1. ELISA. The 96-well ELISA plates (Greiner bio-one;
Germany) were coated with 50μL of synthetic peptide P1 or
P2 (100ng per well) overnight at RT. Unbound synthetic
peptide was washed oﬀ with PBS containing 0.05% Tween 20
(PBST), and sera against P1 or P2 diluted 1:50 in blocking
buﬀer (0.01M PBS containing 5% skim milk powder and
0.05% Tween) were added to the wells (50μL/well) at two-
fold serial dilutions. After incubation for 2h at RT, plates
were washed three times with PBST. To visualize speciﬁc
peptide-antibody reactions, 50μL of goat-anti-rabbit IgG
conjugated to HRP diluted 1:1,000 in PBS was added to
wells and incubated for 1h at RT. All wells were treated with
0.4mgmL−1 o-phenylenediamine and 0.015% (v/v) H2O2
after washing as before and the reaction was stopped with
H2SO4. Finally, the absorbance was read at 490nm, accord-
ing to the manufacturer’s instructions (Thermo Fisher Sci-
entific, Pittsburgh, Pa, USA, Product number 34062T) using
an ELX 800 Universal Microplate Reader (Bio-TEK Instru-
ments, Inc. Vt, USA). For negative control, the same amount
of unrelated P3 synthetic peptide was used for coating the
wells. In addition, rabbit preimmune serum was also used as
negative control
2.6.2. Immunoﬂuorescence. Experiments using human oo-
cytes was approved by the Institutional Ethics Committee.
Human oocytes that had failed to fertilize during in vitro
fertilization (IVF) treatments were kindly donated, and a
signed written consent for use of oocytes was obtained from
all participants. Reactivity of antisera against P1 or P2 with
native human ZP was evaluated by an indirect immunoﬂu-
orescence. Brieﬂy, all oocytes were washed thrice with PBS
containing 1mg mL−1 of polyvinylalcohol (PVA), and then
ﬁxed in 4% (w/v) paraformaldehyde in 50μL of PBS for
5min at RT. Next, the ﬁxed oocytes were washed with PBS-
PVA and incubated for 45min in a blocking solution con-
taining 3% normal goat serum. Further, oocytes were incu-
bated with 1:50 dilution of preimmune or immune sera in
PBS-PVA for 1h at 37◦C after washing with PBS-PVA. Final-
(kDa) 123 456789
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Figure 1: (a) SDS-PAGE analysis of expressed P4–P11 peptides
fused with GST188 protein. (b) Western blotting of each BCE pep-
tide using a mixture of sera to r-hZP3a and r-hZP3b. Lane 1,
prestained protein marker; 2, lanes 2–9, P4–P11 fusion proteins.
Arrows in a-b indicate the bands comprising expressed P4–P11
fusion proteins and their respective bands.
ly, oocytes were treated with 1:500 dilution of Alexa Fluor
568 goat anti-rabbit IgG (Invitrogen, Calif, USA) for 30min
at 37◦C, and after washing, the treated oocytes in PBS-PVA
were examined under a Nikon TE300 inverted microscope
(Nikon Co., Tokyo, Japan).
3. Results
3.1. Reidentiﬁcation of Known and Predictable Linear BCEs
on hZP3 Protein. To determine whether those identi-
ﬁed (hZP3
45–64, 93–110, 137–150, 172–190 and 334–341) and predicted
(hZP3
23–30, 172–181 and 301–320) BCE peptides could be recog-
nized by rabbit sera to r-hZP3a and r-hZP3b, the P4–P11
peptides, which were fused with truncated GST188, were
constructed with DNA recombinant technology. As shown
in Figure 1(a), P4–P11 fusion proteins were expressed in
E. coli. Surprisingly, the electrophoretic mobilities of some
short peptides fused with truncated GST188 did not seem
to match their molecular weight, such as, 20mer P5 protein
(Figure 1(a), Lane 3) migrated similarly to that of 14mer P7
protein (Lane 5) than to that of 18mer P6 protein (Lane 4)
and so on. Although this aberrant behavior cannot be ex-
plained at present, these electrophoretic results should be
reliable as their respective nt sequence matched with the aa
sequence.Further,expressionoftherespectivefusionprotein
was not observed in the uninduced clones (data not shown).
Sixpeptides (P4,P6,P8,P9,P10, andP11)ofhZP3could
be recognized by antiserum against r-hZP3a or r-hZP3b, but
P5 and P7 failed to react with both the immune sera in
Western blot (Figure 1(b)). The results conﬁrmed three BCE
peptides (P6, P9, and P11) of hZP3 out of ﬁve BCE peptides
identiﬁed previously. All three predicted BCE peptides also
reacted with antibodies against r-hZPa/r-hZP3b. In a word,
this study showed that there at least were ﬁve BCE peptides
on hZP3 protein.
3.2.MappingofMinimalMotifsonP4,P6,P9,andP10Epitope
Peptides. Based on initial mapping result, the peptides P4,4 Clinical and Developmental Immunology
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Figure 2: (a) SDS-PAGE analysis of expressed P4 and P12–P15 fusion proteins. (b)–(e) Western blotting of GST188-8mer peptides from P4,
P6, P9, and P10 peptides detected using sera to r-hZP3a or r-hZP3b. Note: M, prestained protein marker; Con, uninduced total cell proteins
as negative control; P4 and P12–46, total cell proteins of expressed P4; P12–P46 8mer peptide fusion proteins.
P6,P9,andP10wereselectedtoidentifytheirminimalmotifs
withserator-hZP3aorr-hZP3b,exceptP11thatitsmotifhas
been known [16]. Four sets of thirty-seven 6–8mer peptides
with an overlap of 5–7 aa residues for P4, P6, P9, and P10
peptide were constructed and used to map minimal motifs
in this study. All P4 and P12 to P46 peptides were expressed
in E. coli at a higher level (Figure 2(a), others not shown). As
showninFigure 2,three(b-c),two(d),aswellasfourandsix
(e) overlapping 6–8mer peptides fused with GST188 were re-
cognized by serum against r-hZP3a or r-hZP3b. These 36
constructs shared sequences of 6 aa (P4 and P6), 7 aa (P9),
a sw e l la s5a aa n d3a a( P 1 0 ) ,r e s p e c t i v e l y( Figure 3).
Thus, their minimal binding motifs were localized to res-
idues QPLWLL23–28,M Q V T D D
103–108, EENWNAE178–184,
SNSWF306–310,a n dE G P 313–315 on the epitope peptides P4,
P6,P9,andP10,ofwhichtwominimalmotifsonpeptideP10
were identiﬁed, suggesting that there were two nested BCEs
on it.
Additionally, we prejudged that the peptide P8 of
hZP3
172–181 should be recognized by serum to r-hZP3b, be-
cause the mapped epitope sequence171–180 of mZP3 [25]i s
100% conserved among mZP3 and hZP3 at the amino acid
level.However,theydidnotgenerateablottedbrownbandat
the position of Stv108-P8 fusion protein when initially using
DAB coloration due to its relatively lower sensitivity (result
not shown). Therefore, a set of P4–P11 peptides fused with
GST188 was again constructed, which were suited to chemo-
luminescence detection on the blotted membrane and then
identiﬁed when using high-sensitivity ECL plus Western
blotting detection reagents. As a result, the peptides P8 and
P9 were recognized by serum to r-hZP3b (Figure 1(b),l a n e s
6-7).Thus,theminimal motif
178–181 ofpeptide P9wasﬁnally
deﬁned according to the shared sequences of 4 aa residues
(EENW) between P8 and the minimal motif of hZP3
178–184
mapped initially.
3.3. Antigenicity of Peptides P1 and P2. To investigate and
compare antigenicity of peptides P1 and P2, each two rabbits
(number 073-074 and number 075-076) were immunized
with synthetic peptide P1 or P2 antigen in FCA, which were
conjugated with KLH. As shown in Figure 4,e a c hp e p t i d e
antigen all elicited higher antibody responses against peptide
P1orP2inimmunizedanimals,ofwhichtherabbit(number
073) immunized with P1 antigen showed antibody titers of
6.4 × 104, whereas that level in the rabbit (number 076)
immunizedwithP2antigenreachedapproximately5.1 ×105
in ELISA assay.
3.4. Speciﬁcity of Antibodies against Peptides P1 and P2. The
rabbit sera against P1 or P2 reacted to not only synthetic
peptide P1 or P2 in ELISA, but also to P9 (hZP3
172–190)o rClinical and Developmental Immunology 5
The position and blotting results of 8mer peptide of hZP
Peptide  Amino          Position Amino
acids
Position
number
Peptide 
number acids in hZP3 in hZP3
P4 QPLWLLQG      
P12 QPLWLLQ           
P13 QPLWLL
P14 PLWLLQ             
P15 LWLLQG          
P16 EVGLHECG
P17 VGLHECGN
P18 GLHECGNS
P19 LHECGNSM
P20 HECGNSMQ
P21 ECGNSMQV
P22 CGNSMQVT
P23 GNSMQVTD
P24 NSMQVTDD
P25 SMQVTDDA
P26 MQVTDDAL
P27 MEENWNAE
P28 EENWNAEK           
P29 ENWNAEKR           
P30 NWNAEKRS           
P31 WNAEKRSP          
P32 NAEKRSPT        
P33 AEKRSPTF        
P34 SFSKPSNS            
P35 FSKPSNSW          
P36 SKPSNSWF
P37 KPSNSWFP         
P38 PSNSWFPV       
P39 SNSWFPVE      
P40 NSWFPVEG       
P41 SWFPVEGP
P42 WFPVEGPA   
P43 FPVEGPAD   
P44 PVEGPADI   
P45 VEGPADIC 
P46 EGPADICQ 
23–30
23–29
23–28
24–29
25–30
93–100
94–101
95–102
96–103
97–104
98–105
99–106
100–107
101–108
102–109
103–110
177–184
178–185
179–186
180–187
181–188
182–189
183–190
301–308
302–309
303–310
304–311
305–312
306–313
307–314
308–315
309–316
310–317
311–318
312–319
313–320
Figure 3: The synthetic 6/8mer peptide sequences from hZP3 protein. The green highlight indicates the common sequence recognized by
antibodies to r-hZP3a or r-hZP3b in P4, P6, P9, and P10 fusion proteins.
P10 (hZP3
301–320)-GST188 fusion protein (Figures 5(a) and
5(b), Lane 2 and 7) as well as native human ZP in indirect
immunoﬂuorescence (Figures 5(i) and 5(j)). As shown in
Figure 5(a), the serum against P1 did not react with Stv108
and GST188 carrier proteins (Lanes 5-6), so does the serum
against P2 (data not shown), suggesting there was no cross-
reactive antibodies with Stv108 and GST188 proteins in their
immune sera. In addition, the serum to P2 reacted to 8mer
peptides P37 and P44 containing a mapped minimal motif
SNFWF or EGP (Figure 5(b), Lanes 9 and 11), conﬁrming
ourabovemappingresult,thatis,thereweretwooverlapping
BCEs within the epitope peptide of hZP3
301–320 (Figure 2(e)
and Figure 5(b)). As shown in Figure 5, the rabbit serum
to P1 or P2 diluted to 1:50 showed a strong positive reac-
tion with the human ZP (I-J), and red ﬂuorescence was ab-
sent when the oocytes were treated with preimmune serum
(g-h). These results showed that production of speciﬁc im-
munoglobulin reactive with P1 or P2 epitope peptide and
with human ZP was elicited by P1 or P2 peptide in immu-
nized rabbits, respectively.
4. Discussion
The hZP3 protein has been an interesting target antigen for
the development of a contraceptive peptide vaccine. Two
BCEs137–150 and 334–341 on hZP3 were ﬁrst identiﬁed with se-
rum to each synthetic peptide based on computer prediction
or sequence comparison of a known BCE sequence of mZP3
with other ZP3 protein in many mammals [15, 16]. The for-
mer 14 mer peptide
137–150 ( P 7 )o fh Z P 3 ,h o w e v e r ,w a sn o t
recognized by both sera to r-hZP3 in ELISA [17] and serum
to r-hZP3a in Western blotting (Figure 1(b), Lane 5), sug-
gestingthatitmightnotbeaself-epitopepeptideofhZP3,al-
though it could elicit antibody capable of binding to native
hZP and its antiserum might be used as a marker for the
identiﬁcation of hZP3 protein [15]. For the latter 8 mer
peptide
334–341 (P11) that elicited antibodies reacting to hu-
manZPintransgenicmice[16],althoughitfailedtobeiden-
tiﬁed by serum to r-hZP3 in the study on epitope mapping
of hZP3
22–360 [17], the result that peptide P11 could be
recognized by serum to r-hZP3b in this study (Figure 1(b),
lane 9) suggested that it should be an epitope of hZP3. As
well, the 20 mer peptide
45–64 (P5) of hZP3 mapped by se-
rum to r-hZP3 [17], it could not react to serum to r-hZP3b
in this study (Figure 1(b), Lane 3). At present, we cannot
explain these distinct mapping results, including the above-
mentioned 8mer peptide
334–341, because both groups
employed diﬀerent antisera (against r-hZP3
22–460 and
r-hZP3a
22–176,r e s p . ) .
The antigenicity and immunogenicity of hZP3
172–190
[17], mstZP3
301–320 [18, 26], and bmZP3
300–322 [27]w e r e
previously reported. These synthetic peptides elicited anti-
bodies capable of reacting to native mstZP, bmZP, and hZP,6 Clinical and Developmental Immunology
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Dilution of antiresum to antigen P1 or P2
Figure 4: Comparison antibody titers to synthetic P1 and P2
of hZP3. The antibody levels were determined by ELISA using
synthetic P1 () and P2 () peptide as antigens. Normal rabbit
serum (•) and or P3 (not shown) were used as negative controls.
Titers were determined based on the highest dilution of the sample
that generated OD greater 0.2.
respectively. The peptide sequence301–320 is highly conserved
between mstZP3 and bmZP3 sequences. The mst-serum
tomstZP3
301–320 linked to a promiscuous helper TCE from
tetanus toxoid showed up to 60% of inhibition in human
sperm-zona binding in vitro [26]. Conversely, the bm-serum
to bmZP3
300–322 conjugated to diphtheria toxoid failed to
showanysigniﬁcantdecreaseinsperm-zonabindinginhem-
izona assay [27]. The reasons for this discordance are not
clear and more research is required to explain these ﬁndings.
In the present study, because there is diﬀerence of one re-
sidueattheposition305 ofhZP3
301–320 (P),mstZP3
301–320 (A),
andbmZP3
301–320 (S),itsantigenicityandspeciﬁcitywaspre-
liminarily evaluated using synthetic peptide P2 conjugated
with KLH, and was compared with peptide P1. As shown
in Figures 4 and 5, peptides P1 and P2 elicited high-titer
antibodies reacting with native hZP and r-hZP3b peptide
expressed in E. coli, but the antigenicity of the latter was
signiﬁcantlygreaterthanthatoftheformer.Fortheantigenic
diversity of peptides P1 and P2, one possible explanation
might be because there were antibodies against two over-
lapping BCEs (NSNWF306–310 and EGP313–315) within the
peptide P2 sequence. As for the eﬃcacy of each antiserum to
inhibit human sperm-zona binding, it remains to be further
evaluated by carrying out competitive hemizona or sperm-
egg binding assays.
The serum to a synthetic peptide was often used to map
minimal motif of identiﬁed BCE peptide [16, 28]. To further
check the speciﬁcity of peptides P1 and P2 as antigen, the
Western blotting was carried out with two sets of 8 mer pep-
tides (P27∼P33 and P34∼P46). Surprisingly, the rabbit se-
rum to P1 not only could recognize peptides P28 and P29,
but also reacted with peptides P30 and P31 that were not re-
cognized by rabbit serum to r-hZP3b, whereas the serum to
P2 only recognized peptides P42 and P43, but did not recog-
nize other peptides (P43–P46) reacted with serum to r-
hZP3b (data not shown). The data suggested that their BCE
motifs generated a “drifting” phenomenon when using se-
rum against synthetic peptide P1 or P2 to map minimal mo-
tif compared with the result identiﬁed with serum to r-
hZP3b, that is, the minimal motifs mapped with serum to
a synthetic peptide and to a native or r-protein might be dif-
ferent sometimes.
The synthetic peptides method [29–31]h a sb e e no f t e n
used to delineate linear BCEs on a protein; however, the
number of mapped BCE always was less or some BCEs were
missing when using serum to r-protein and ELISA. For in-
stances the following hold. (1) Only 3 BCEs on hZP3, not
including a BCE on its C-terminus transmembrane- like
domain, were mapped with serum to CHO-expressed
r-hZP3
22–460 [17] compared with the result of mapped 6
BCEs in this study. (2) It could not be deﬁned how many
BCEs there were in six of potential reactive neighboring
15mer-peptides (P5–P8, P11-P12, P14–P18, P31–P33, P38-
P39, and P43-P44) in the epitope mapping of brushtail
possum(bp)ZP2
40–634 withserator-bpZP2
40–311/305–634 [32],
whichmightbeoneofcauseswhyseveralBCEpeptidescould
be missed or could not be deﬁned in above two epitope map-
ping studies using synthetic peptide library. As we know,
there may be only one BCE on mapped two neighboring
overlapping peptides because they share a common sequence
[33], but there may also be two or three BCEs according to
our other epitope mapping results of E6, E7, and L1 proteins
from HPV type 58 virus (data not shown). It obviously is a
drawback to employ this method to map all BCEs on a pro-
tein, because it could not be used to carry out minimal motif
identiﬁcation of each reactive neighboring peptide with se-
rum to r-protein, which is a way of answering how many
BCEs there are on them.
Some studies on expression of single 4–12mer BCE pep-
tides fused with Stv118 core protein [34] and epitope map-
ping with several puriﬁed short peptides fused with GST226
[35, 36], suggested the possibility of using biosynthetic pep-
tides to map linear BCEs and their minimal motifs on a pro-
tein. However, not like the above studies using mAb, chicken
sera to SARS-CoV, and SARS convalescent sera, it needs to
solve a key problem to employ serum against r-protein, that
is, how to avoid interfering of antibodies against some strong
antigens from E. coli on distinguishing target blotted bands.
Because any r-protein used as immunogen always contains a
little bacteria proteins that could not be completely removed
when puriﬁed at laboratory level. At present, this problem
has been solved through using a truncated GST188 or Stv108
as carrier of short peptide expression. As showed in Figure 1,
the blotted bands of the GST188-short peptides were to be
located in a weak antigenic area of bacterial proteins on blot-
ted membrane, which avoided two blotted bands of bacterial
protein with 21kDa and 31kDa bands. Obviously, besides
simple, cheap, reliable, and adaptable merits mentioned in
our previous work [20], the present study showed another
twodistinctadvantagesofourimprovedbiosyntheticpeptide
strategy: (1) it permits using serum against bacteria-ex-
pressed protein to map BCEs and their minimal motifs onClinical and Developmental Immunology 7
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Figure 5: (a-b) Western blotting with sera to P1 or P2. Lane 1, prestained protein marker; Lanes 2 and 3, induced and uninduced
GST-hZP3
172–190; Lanes 4 and 13, induced hZP3b
177–348; Lanes 5 and 6, induced Stv108 and GST188; Lanes 7 and 8, induced and uninduced
GST-hZP3
301–320; Lanes 9 and 10, induced and un-induced GST-P37; Lanes 11 and 12, induced and un-induced GST-P44. (c–f) matching
light images for the human oocytes imaged by immunoﬂuorescence in panels g–j. (g–j) reactivity of rabbit sera to P1 or P2 with human
oocyte by indirect immunoﬂuorescence. Representative immunoﬂuorescence patterns are shown for (g) preimmune serum; (h) immune
serum only received CFA (i-j) immune serum to P1 or P2.
the target protein; (2) the 8mer–20mer peptide fusion pro-
teins expressed by pXXGST-1 or pXXStv-3 plasmid could be
used in Western blotting without purifying. In addition, the
smallest binding motif of 3 residues for antibodies can be de-
ﬁned with biosynthetic peptides (Figure 2(e) and Figure 3),
whereas the length mapped with synthetic peptides method
was 4-5 residues [37].
In summary, this study is the ﬁrst to utilize biosynthetic
peptides and sera against r-hZP3a and/or r-hZP3b to map
BCEs and their minimal motifs on hZP3 protein. The identi-
ﬁcation of ﬁve minimal motifs within four epitopes on hZP3
will help in developing contraceptive vaccines of multiepi-
tope ZP peptides without ZP-speciﬁc TCE activities which
may result in ovarian dysfunction for human use in future,
and those deﬁned BCE minimal motifs of hZP3 would be
also used as speciﬁc probes to detect whether there are self-
ZP antibodies to each BCE in the sera from patients with in-
fertile and/or premature ovarian failure. Furthermore, the
datapresentedhereagainclearlysuggestthatthebiosynthetic
peptide strategyemployedinthis studycouldbeusedtomap
all BCEs and precise linear epitopes on other entire ZP pro-
teins in any species.
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